A full 14 years after founding CRO Clinipace, its longstanding CEO and president Jeff Williams is to step down.
The chief’s role will be handed over to Jason Monteleone, who founded Pivotal Financial Consulting, a consulting firm with a focus on CROs, while Williams moves into an “expanded advisory role” within the board, according to a statement.
“I am extremely proud of what we have built at Clinipace, but the time has come for me to replace myself and it is my pleasure to welcome Jason Monteleone as CEO,” said Williams.
“After seeing him in action as a consultant to Clinipace over the last several months, I am confident he will build successfully on our company’s 14-year history and lead us into its next phase of growth.”
Williams has over the past three years been an acquisitive chief, buying up European CRO Accovion as well as Hong Kong CRO Choice Pharma, Paragon Biomedical, PFC Pharma, Regulus Pharmaceutical and Worldwide Clinical Research.
It now has more than 800 staffers and has completed more than 1,500 clinical trials.
Monteleone added: “I am honored to join Clinipace on the heels of the remarkable accomplishments that Jeff and his organization have achieved. I am confident that the strong foundation he built, and the talented team here, will serve us well as we continue our quest to make Clinipace the leading mid-market CRO.”
By Ben Adams
Source: Fierce Biotech
UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).
GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.